

John D Pauling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3732992/publications.pdf>

Version: 2024-02-01

91
papers

1,542
citations

304743

22
h-index

361022

35
g-index

94
all docs

94
docs citations

94
times ranked

1735
citing authors

#	ARTICLE	IF	CITATIONS
1	Raynaud phenomenon and digital ulcers in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 208-221.	8.0	115
2	Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, 912-921.	1.9	77
3	VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1269.	4.1	75
4	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2019, 5, e001014.	3.8	73
5	Raynaud's phenomenon—an update on diagnosis, classification and management. <i>Clinical Rheumatology</i> , 2019, 38, 3317-3330.	2.2	67
6	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography. <i>Arthritis and Rheumatology</i> , 2018, 70, 903-911.	5.6	65
7	Gender-related differences in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102494.	5.8	55
8	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018, 70, 1373-1384.	3.4	54
9	Mortality in systemic sclerosis—a single centre study from the UK. <i>Clinical Rheumatology</i> , 2013, 32, 1533-1539.	2.2	49
10	Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 482-494.	3.4	48
11	Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary. <i>Journal of Rheumatology</i> , 2015, 42, 1163-1168.	2.0	44
12	Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 712-717.	1.9	39
13	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, 18-26.	1.9	37
14	Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools. <i>Clinical Rheumatology</i> , 2012, 31, 1215-1222.	2.2	35
15	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.7	33
16	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. <i>Arthritis Care and Research</i> , 2017, 69, 783-793.	3.4	32
17	Exploring the patient experience of digital ulcers in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 888-894.	3.4	28
18	Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S103-15.	0.8	28

#	ARTICLE	IF	CITATIONS
19	Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 170-174.	1.7	27
20	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1049-1058.	5.6	27
21	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2019, 58, 2162-2169.	1.9	26
22	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020, 72, 723-733.	3.4	25
23	Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 1326-1334.	2.0	24
24	Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity. <i>Arthritis Care and Research</i> , 2019, 71, 1119-1126.	3.4	23
25	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101707.	3.3	22
26	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	1.9	20
27	The efficacy of dietary intervention on gastrointestinal involvement in systemic sclerosis: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 112-118.	3.4	18
28	Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al. <i>Arthritis and Rheumatology</i> , 2018, 70, 973-974.	5.6	16
29	Symptoms of Raynaud's phenomenon (RP) in fibromyalgia syndrome are similar to those reported in primary RP despite differences in objective assessment of digital microvascular function and morphology. <i>Rheumatology International</i> , 2016, 36, 1371-1377.	3.0	14
30	Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?. <i>Rheumatology</i> , 2020, 59, 464-466.	1.9	14
31	Patient-reported outcome instruments in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 90-102.	1.7	14
32	High-frequency Ultrasound Assessment of Systemic Sclerosis Skin Involvement: Intraobserver Repeatability and Relationship With Clinician Assessment and Dermal Collagen Content. <i>Journal of Rheumatology</i> , 2021, 48, 867-876.	2.0	14
33	Increased number of cases of giant cell arteritis and higher rates of ophthalmic involvement during the era of COVID-19. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa067.	0.7	14
34	Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization – WSF Skin Ultrasound Group. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151954.	3.4	14
35	An interim report of the Scleroderma Clinical Trials Consortium working groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 17-27.	1.7	13
36	The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 431-442.	3.0	12

#	ARTICLE	IF	CITATIONS
37	Epidemiology of systemic sclerosis in the UK: an analysis of the Clinical Practice Research Datalink. <i>Rheumatology</i> , 2021, 60, 2688-2696.	1.9	12
38	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 66-76.	1.7	12
39	How do patients define Raynaud's phenomenon? Differences between primary and secondary disease. <i>Clinical Rheumatology</i> , 2021, 40, 1611-1616.	2.2	12
40	Impact of Covid-19 on clinical care and lived experience of systemic sclerosis: An international survey from EURORDIS-Rare Diseases Europe. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 133-138.	1.7	12
41	The prognostic value of cardiopulmonary exercise testing in interstitial lung disease: a systematic review. <i>ERJ Open Research</i> , 2020, 6, 00027-2020.	2.6	11
42	Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1114-1130.	3.4	11
43	Patient experiences of digital ulcer development and evolution in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 2156-2158.	1.9	11
44	Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure. <i>Rheumatology</i> , 2021, 60, 4671-4680.	1.9	11
45	Sublingual Abnormalities in Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2016, 22, 19-21.	0.9	10
46	Behaviour change interventions for the management of Raynaud's phenomenon: a systematic literature review. <i>BMJ Open</i> , 2018, 8, e024528.	1.9	10
47	Patient organisation-led initiatives can play an important role in raising awareness about Raynaud's phenomenon and encourage earlier healthcare utilisation for high-risk groups. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 439-441.	0.9	9
48	Factors influencing patient decision-making concerning treatment escalation in Raynaud's phenomenon secondary to systemic sclerosis. <i>Arthritis Care and Research</i> , 2021, 73, 1845-1852.	3.4	9
49	Qualitative Methods to Advance Care, Diagnosis, and Therapy in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 267-284.	1.9	8
50	Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 85-103.	1.4	8
51	Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 831-835.	1.9	8
52	Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. <i>Rheumatology</i> , 2020, 59, 1709-1714.	1.9	8
53	Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 640-643.	3.4	8
54	Patient participation in patient-reported outcome instrument development in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 184-192.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Evaluating factors influencing screening for pulmonary hypertension in systemic sclerosis: does disparity between available guidelines influence clinical practice?. <i>Clinical Rheumatology</i> , 2012, 31, 357-361.	2.2	6
56	Multidisciplinary collaboration among young specialists: results of an international survey by the emerging EULAR network and other young organisations. <i>RMD Open</i> , 2020, 6, e001398.	3.8	6
57	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. <i>BMJ Open</i> , 2021, 11, e044765.	1.9	6
58	The clinicoserological spectrum of inflammatory myopathy in the context of systemic sclerosis and systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , 2020, 15, 81.	0.4	6
59	Vacuum-assisted closure therapy: a novel treatment for wound healing in systemic sclerosis. <i>Rheumatology</i> , 2011, 50, 420-422.	1.9	5
60	Vasodilation is not the only approach to the management of cutaneous ulceration in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, 1559-1559.	1.9	5
61	The Clinical Aspects of Autoantibodies. , 2012, , 209-225.		4
62	What narrative devices do people with systemic sclerosis use to describe the experience of pain from digital ulcers: a multicentre focus group study at UK scleroderma centres. <i>BMJ Open</i> , 2020, 10, e037568.	1.9	4
63	Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders. <i>Clinical Rheumatology</i> , 2021, 40, 2457-2465.	2.2	4
64	The aetiopathogenic significance, clinical relevance and therapeutic implications of vasculopathy in idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2021, 60, 1593-1607.	1.9	4
65	Non-invasive Methods of Assessing Raynaud's Phenomenon. , 2015, , 199-242.		4
66	Behaviour change interventions for the management of Raynaud's phenomenon: a systematic review protocol. <i>BMJ Open</i> , 2017, 7, e017039.	1.9	3
67	Fulminant immune-mediated necrotising myopathy (IMNM) mimicking myocardial infarction with non-obstructive coronary arteries (MINOCA). <i>BMJ Case Reports</i> , 2020, 13, e236603.	0.5	3
68	Effect of Coping Strategies on Patient and Physician Perceptions of Disease Severity and Disability in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1569-1573.	2.0	3
69	Evaluation of a patient self-stratification methodology to identify those in need of shielding during COVID-19. <i>Clinical Medicine</i> , 2020, 20, e212-e214.	1.9	2
70	The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis. <i>Clinical Rheumatology</i> , 2022, , .	2.2	2
71	Could nailfold videocapillaroscopy usher in a new era of preventative disease-modifying therapeutic intervention in systemic sclerosis?. <i>Rheumatology</i> , 2016, 56, kew461.	1.9	1
72	O16 A study examining the reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: challenges and insights for future clinical trial design. <i>Rheumatology</i> , 2018, 57, .	1.9	1

#	ARTICLE	IF	CITATIONS
73	Lindsay's Nails in Early Limited Cutaneous Systemic Sclerosis With Severe Digital Vasculopathy. <i>Arthritis and Rheumatology</i> , 2021, 73, 1004-1004.	5.6	1
74	Agreement between physician evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS). <i>Arthritis Care and Research</i> , 0, , .	3.4	1
75	Autoantibodies in Raynaud's Phenomenon. , 2015, , 253-266.		1
76	Treatment efficacy in secondary Raynaud's phenomenon. <i>Lancet Rheumatology</i> , The, 2020, 2, e132.	3.9	1
77	Differing commissioning arrangements may contribute to geographic variation in clinical management of digital ulcers in systemic sclerosis. <i>Clinical Medicine</i> , 2020, 20, 343-345.	1.9	1
78	Development of Local Guidelines for the Management of Patients on Biologic Therapy Following Exposure to or Infection with Varicella Zoster Virus. <i>Rheumatology</i> , 2014, 53, i117-i118.	1.9	0
79	A longitudinal analysis of prevalence of sustained remission and low disease activity in rheumatoid arthritis patients treated with anti-tumour necrosis factor: an analysis of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2018, 57, .	1.9	0
80	Limitations in study design hamper interpretation of studies evaluating the prognostic value of nailfold capillaroscopy in systemic sclerosis: a systematic literature review. <i>Rheumatology</i> , 2018, 57, .	1.9	0
81	Changes in the management of systemic sclerosis-related digital ulcer disease between 2015-2017 across devolved nations of the United Kingdom: a multi-centre service evaluation project across South West England and Wales. <i>Rheumatology</i> , 2019, 58, .	1.9	0
82	The efficacy of dietary intervention on gastrointestinal involvement in systemic sclerosis: a systematic literature review. <i>Rheumatology</i> , 2019, 58, .	1.9	0
83	Influence of season on patient-reported assessment of Raynaud's severity in patients with systemic sclerosis. <i>Rheumatology</i> , 2019, 58, .	1.9	0
84	Cutaneous vascular manifestations of systemic sclerosis and related disorders. <i>Rheumatology</i> , 2019, 58, .	1.9	0
85	Vasculopathy: better assessment of Raynaud's phenomenon and digital ulcers in scleroderma. <i>Rheumatology</i> , 2019, 58, .	1.9	0
86	EULAR POINTS TO CONSIDER FOR THE DEVELOPMENT, EVALUATION AND IMPLEMENTATION OF MOBILE HEALTH APPLICATIONS FOR SELF-MANAGEMENT IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES. , 2019, , .		0
87	Pauling and Frech reply. <i>Journal of Rheumatology</i> , 2019, 46, 1544-1545.	2.0	0
88	Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic-related digital vasculopathy: a systematic literature review. <i>Rheumatology</i> , 2021, 60, .	1.9	0
89	Raynaud's Phenomenon. In <i>Clinical Practice</i> , 2021, , 67-77.	0.0	0
90	Systemic sclerosis: what's in a name?. <i>Lancet Rheumatology</i> , The, 2021, 3, e820-e821.	3.9	0

#	ARTICLE	IF	CITATIONS
91	P293â€¦Tocilizumab for refractory or relapsing giant cell arteritis: audit data from the Bristol and Bath regional multidisciplinary meetings 2018-2021. Rheumatology, 2022, 61, .	1.9	0